Innovation Pharmaceuticals Inc (IPIX)

[Truthbythought]

The reason why restaging to stable disease followed by progression did not impress is conveniently summed up in this abstract from 2009:

"With a high percentage of new oncologic agents failing in phase III studies, the confidence one has in predicting later success in randomized studies when stable disease alone is observed is understandably low. Continued uncertainty of the value of stable disease is based on the lack of precision in defining this as a meaningful outcome. With the term stable disease encompassing a broad range from <20% enlargement to <30% reduction using standard response criteria response evaluation criteria in solid tumors, what one refers to as stable disease is open to diverse interpretation."